DOCSLIB.ORG

Cannabis Policy and Legislation in the Nordic Countries

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis Policy and Legislation in the Nordic Countries Cannabis policy and legislation in the Nordic countries A report on the control of cannabis use and possession in the Nordic legal systems Cannabis policy and legislation in the Nordic countries A report on the control of cannabis use and possession in the Nordic legal systems Published by Nordic Welfare Centre © 2019 Project manager: Yaira Obstbaum Authors: Susanne Egnell, Emma Villman, Yaira Obstbaum Responsible publisher: Eva Franzén ISBN: 978-91-88213-38-9 Nordic Welfare Centre Box 1073, SE-101 39 Stockholm Visiting Adress: Drottninggatan 30 Phone: +46 8 545 536 00 [email protected] Nordic Welfare Centre c/o Folkhälsan FI-00250 Helsinki Visiting Adress: Topeliusgatan 20 Phone: +358 20 741 08 80 [email protected] The report can be downloaded at nordicwelfare.org/en/publikationer 2 Preface How do the Nordic countries control cannabis use in their legal systems? How do the Nordic legal systems see cannabis as a drug in 2018, and how does this affect the cannabis user? This report looks at the similarities and differences in legisla- tion and the ways in which the law is enacted in legal practice, police work, and many other arenas. While the Nordic countries have relatively similar criminal policies as a whole, there are some striking differences in their dealing with drugs such as cannabis. We therefore survey the legislative differences and similarities in this five-country report in close detail. The country profiles zoom in on the legal control of cannabis on the basis of a large body of secondary material, academic literature, and reports as well as data from Nordic statistical bureaus. The authors have also conducted interviews with researchers and representatives of the legal system to address an evident lack of research on the practicalities of policing and sanctioning of cannabis use. Emma Villman has written the chapter on Finland, while the sections on Den- mark, Iceland, Norway and Sweden were authored by Susanne Egnell. The intro- ductory chapters were written by Yaira Obstbaum-Federley. The report was produced in a project financed by the Nordic Arena for Public Health Issues. We encourage the readers to read another result from this project, the report Cannabis-related problems in the Nordic Countries (Stenius, 2019), which is available at the Nordic Welfare Centre's website nordicwelfare.org. The findings of the report on cannabis control in the Nordic legal systems were discussed by a Nordic expert group consisting of Mats Anderberg, Susanne Egnell, Helgi Gunnlaugsson, Pekka Hakkarainen, Karoliina Karjalainen, Aarne Kinnunen, Paul Larsson, Maj Nygaard-Christensen, Yaira Obstbaum-Federley, Rafn Magnús Jónsson, Karin Rantala, Nina Rehn-Mendoza, Kristine Rømer Thom-sen, Mette Irmgard Snertingdal, Kerstin Stenius, Henrik Tham, Per Ole Träsk-man and Emma Villman. We want to extend a heartfelt thank you to the expert group. We also wish to thank Jessica Gustafsson, Pirkko Hautamäki, Heini Kai- nulainen, Nina Karlsson Leena Metsäpelto and Nina Rehn-Mendoza. 3 We hope this report will be of interest and inspiration for researchers, experts in judicial matters as well as in social studies, and experts working with these mat- ters in government organisations and in third sector organisations and anyone interested in these questions. Eva Franzén Director, Nordic Welfare Centre 4 Contents Preface .............................................................................................................. 3 Terminology ...................................................................................................... 8 Why should we study the legal control of cannabis from a Nordic perspective? Reasons and statistics ....................................................................................... 9 References ....................................................................................................... 13 Cannabis use in the Nordic countries ................................................................ 15 References ....................................................................................................... 17 Cannabis control in Denmark ........................................................................... 19 Danish drug laws ...................................................................................... 20 Medical cannabis ............................................................................... 21 Police-registered drug offences ................................................................ 21 Cannabis in police-registered offences .............................................. 23 Drug-impaired driving ....................................................................... 23 Who is controlled? ............................................................................. 25 Cannabis on the Danish illicit drug market ................................................ 27 Synthetic cannabinoids ..................................................................... 28 Penalty assessment and case law ............................................................. 29 Penal sanctions system .............................................................................. 31 Fines and imprisonment .................................................................... 32 Waiving of measures .......................................................................... 33 Alternative or mixed sanctions .......................................................... 34 Youth sanctions ..................................................................................35 Treatment in prison ........................................................................... 36 Criminal record ................................................................................... 37 Summary: Denmark ........................................................................................ 38 References ...................................................................................................... 40 Cannabis control in Finland .............................................................................. 45 Finnish drug legislation ............................................................................. 45 Drug use offences (50:2a§) ................................................................. 45 Narcotics offences (50:1§) .................................................................. 47 Aggravated narcotics offences (50:2§) ............................................... 47 Medical cannabis ............................................................................... 48 Changes in the legislation .................................................................. 48 Police-registered drug offences ................................................................ 48 Who is controlled? .................................................................................... 50 Cannabis on the Finnish illicit drug market ................................................. 51 Cannabis in police-registered offences ..................................................... 52 Penal sanctions system ..............................................................................53 5 Waiving of measures ....................................................................... 55 Summary: Finland ..................................................................................... 57 References ...................................................................................................... 58 Cannabis control in Iceland .............................................................................. 62 Icelandic drug legislation .......................................................................... 63 Medical cannabis ............................................................................... 63 Police-registered drug offences ................................................................ 63 Drug-impaired driving ....................................................................... 65 What do we know about the Icelandic cannabis market? .......................... 67 Penalty levels and case law ....................................................................... 69 Penal sanctions system ............................................................................. 72 Waiving of measures .......................................................................... 73 Criminal record .................................................................................. 74 Summary: Iceland ............................................................................................ 75 References ...................................................................................................... 76 Cannabis control in Norway ............................................................................. 79 Norwegian drug legislation ....................................................................... 80 Medical cannabis ............................................................................... 81 Police-registered drug offences ................................................................ 81 Cannabis in police-registered offences .............................................. 83 Drug-impaired driving ....................................................................... 84 Who is controlled? ............................................................................. 86 Cannabis on the Norwegian illegal drug market ........................................ 88 Synthetic cannabinoids
Load more

Recommended publications
  • Accepted Manuscript
    Accepted Manuscript Title: Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries Author: Pekka Hakkarainen Vibeke Asmussen Frank Monica J. Barratt Helle Vibeke Dahl Tom Decorte Karoliina Karjalainen Simon Lenton Gary Potter Bernd Werse PII: S0955-3959(14)00173-X DOI: http://dx.doi.org/doi:10.1016/j.drugpo.2014.07.005 Reference: DRUPOL 1418 To appear in: International Journal of Drug Policy Received date: 18-4-2014 Revised date: 4-7-2014 Accepted date: 7-7-2014 Please cite this article as: Hakkarainen, P., Frank, V. A., Barratt, M. J., Dahl, H. V., Decorte, T., Karjalainen, K., Lenton, S., Potter, G., and Werse, B.,Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries, International Journal of Drug Policy (2014), http://dx.doi.org/10.1016/j.drugpo.2014.07.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries Pekka Hakkarainen1, Vibeke Asmussen Frank2, Monica J. Barratt3,6, Helle Vibeke Dahl2, Tom Decorte4, Karoliina Karjalainen5, Simon Lenton6, Gary Potter7 & Bernd Werse8 1 Corresponding author, Department of Alcohol, Drugs and Addiction, National Institute for Health and Welfare (THL), P.O.
    [Show full text]
  • PDF (Book of Abstracts)
    Ninth Annual Conference of the International Society for the Study of Drug Policy Ghent (Belgium) – 20 – 22 May 2015 Venue: Het Pand With the financial support of Book of Abstracts i ISSDP conference 20-22 May 2015 Book of Abstracts Table of Contents KEYNOTE SPEAKERS ......................................................................................................................................... 5 ABDOOL, REYCHAD ................................................................................................................................................ 6 BERRIDGE, VIRGINIA .............................................................................................................................................. 7 KRAUS, LUDWIG .................................................................................................................................................... 8 MASAO, FRANK ..................................................................................................................................................... 9 MOORE, DAVID ................................................................................................................................................... 10 TOUFIQ, JALLAL ................................................................................................................................................... 11 ORAL PRESENTATIONS ................................................................................................................................... 13 AHMED, TANVIR
    [Show full text]
  • This Is the Peer Reviewed Version of the Following Article
    This is the peer reviewed version of the following article: Potter, G. R., Barratt, M. J., Malm, A., Bouchard, M., Blok, T., Christensen, A.-S., Decorte, T., Frank, V. A., Hakkarainen, P., Klein, A., Lenton, S., Perälä, J., Werse, B., & Wouters, M. (2015). Global patterns of domestic cannabis cultivation: Sample characteristics and patterns of growing across eleven countries. International Journal of Drug Policy, 26(3), 226–237. which has been published in final form at https://doi.org/10.1016/j.drugpo.2014.12.007 This article may be used for non-commercial purposes in accordance with Elsevier’s Article Sharing policy and Hosting policy © 2014. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Accepted Manuscript Title: Global patterns of domestic cannabis cultivation: Sample characteristics and patterns of growing across eleven countries Author: Gary R. Potter Monica J. Barratt Aili Malm Martin Bouchard Thomas Blok Anne-Sofie Christensen Tom Decorte Vibeke Asmussen Frank Pekka Hakkarainen Axel Klein Simon Lenton Jussi Peral¨ a¨ Bernd Werse Marije Wouters PII: S0955-3959(14)00363-6 DOI: http://dx.doi.org/doi:10.1016/j.drugpo.2014.12.007 Reference: DRUPOL 1503 To appear in: International Journal of Drug Policy Received date: 22-7-2014 Revised date: 6-12-2014 Accepted date: 8-12-2014 Please cite this article as: Potter, G. R., Barratt, M. J., Malm, A., Bouchard, M., Blok, T., Christensen, A.-S., Decorte, T., Frank, V. A., Hakkarainen, P., Klein, A., Lenton, S., Peral¨ a,¨ J., Werse, B., and Wouters, M.,Global patterns of domestic cannabis cultivation: sample characteristics and patterns of growing across eleven countries, International Journal of Drug Policy (2014), http://dx.doi.org/10.1016/j.drugpo.2014.12.007 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Cannabis Regulation in Europe: Country Report Denmark
    COUNTRY REPORT | February 2019 Cannabis Regulation in Europe: Country Report Denmark Maj Nygaard-Christensen and Vibeke Asmussen Frank Aarhus University ideas into movement Introduction This report examines policy and practice relating to the regulation of cannabis in Denmark. It was produced as part of a study of cannabis regulation models in Europe, funded by the European Commission and led by the Transnational Institute in Amsterdam. The broader study examines and compares experiences from European countries’ experiments with cannabis regulation, including trial proposals for legalisation or decriminalisation of cannabis use, with a particular focus on larger cities in six countries. Denmark has no legal regulation regarding recreational cannabis use, and possession, production, import/export, and buying and selling of cannabis is illegal (Dahl and Frank 2012: 13). This overview of the legal and policy framework for the regulation of cannabis first introduces the policy shifts in cannabis control in Denmark, reviews the political positions on possibilities for legalisation or decriminalisation, and the international context influencing these. It then offers an analysis of how policy and police crackdowns on the open-air cannabis market in Christiania in Copenhagen led to a dispersal and restructuring of the market, with the entry of new criminal gangs. This part of the report indicates an increasingly repressive cannabis policy in Denmark, although there are some openings in the form of a trial for medicinal cannabis commencing in 2018, and a proposed model for legalised cannabis in Copenhagen Municipality. From Tolerant to Repressive Cannabis Control Cannabis falls under the 1955 Euphoriant Substances Act, which is used for minor offences that can be punished with up to a two-year prison term, and the penal code’s §191 from 1969, which refers to the organised sale and possession of larger amounts of narcotics.
    [Show full text]
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Medicinal Use of Cannabis 3Rd Edition
    M E M O R A N D U M Medicinal use of Cannabis 3rd edition 2015 04/12/2015 Medicines Control & Inspection File no.2013113424/ Axel Heides Gade 1 DK-2300 Copenhagen S Frank Bøgh Madsen [email protected] Email: [email protected] Page 2 04/12/2015 Danish Medicines Agency Contents 1. Introduction ................................................................................................ 3 2. The body's own cannabinoids and receptors .............................................. 3 3. Knowledge about intoxicating and harmful effects and the prevalence of Cannabis......................................................................................................... 4 3.1. The Dutch Ministry of Health's brochure about side effects of medicinal use of Cannabis .......................................................................................... 5 4. Rules about Cannabis as a euphoriant substance ....................................... 6 4.1. List A – Cannabis ............................................................................... 6 4.2. List B – THC in pure form and other cannabinoids ............................ 7 4.3. CBD – in pure form or in hemp products ............................................ 8 5. Positive effects of medicines containing active substances from Cannabis and clinical trials ............................................................................................ 8 5.1. Other scientific evidence about Cannabis and cannabinoids ............ 10 6. Rules about medicines requiring a marketing authorisation (Sativex®)
    [Show full text]
  • Paterson Title
    Prohibition & Resistance: A Socio-Political Exploration of the Changing Dynamics of the Southern African Cannabis Trade, c. 1850 – the present. A thesis in fulfilment of the requirements for the degree of Master of Arts in History at Rhodes University By Craig Paterson December 2009 Abstract Looking primarily at the social and political trends in South Africa over the course of the last century and a half, this thesis explores how these trends have contributed to the establishment of the southern Africa cannabis complex. Through an examination of the influence which the colonial paradigm based on Social Darwinian thinking had on the understanding of the cannabis plant in southern Africa, it is argued that cannabis prohibition and apartheid laws rested on the same ideological foundation. This thesis goes on to argue that the dynamics of cannabis production and trade can be understood in terms of the interplay between the two themes of ‘prohibition’ and ‘resistance’. Prohibition is not only understood to refer to cannabis laws, but also to the proscription of inter-racial contact and segregation dictated by the apartheid regime. Resistance, then, refers to both resistance to apartheid and resistance to cannabis laws in this thesis. Including discussions on the hippie movement and development of the world trade, the anti-apartheid movement, the successful implementation of import substitution strategies in Europe and North America from the 1980’s, and South Africa’s incorporation into the global trade, this thesis illustrates how the apartheid system (and its collapse) influenced the region’s cannabis trade. Keywords: anti-apartheid movement, apartheid, colonialism, cannabis prohibition, cannabis trade, dagga, hippie movement, southern African cannabis complex Table of Contents Introduction and Overview………………………………………………………………p.
    [Show full text]
  • MEDICAL CANNABIS in EUROPE: the Markets & Opportunities SECOND EDITION
    MEDICAL CANNABIS IN EUROPE: The Markets & Opportunities SECOND EDITION In-depth look at key European markets and the regulations companies need to understand to tap these revenue opportunities © 2020 Anne Holland Ventures Inc. All Rights Reserved Medical cannabis for German patients We purchase and import EU-GMP medical cannabis into Germany and sell to pharmaceutical wholesalers who supply to pharmacists Subscribe to our newsletter at amp-eu.com/learnmore Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl TABLE OF CONTENTS WLECOME LETTER 5 EU MARKET AT A GLANCE 9 GERMANY 14 ITALY 43 THE NETHERLANDS 55 DENMARK 65 CZECH REPUBLIC 74 AUSTRIA AND SWITZERLAND 78 OTHER SMALL MARKETS 80 3 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. RESEARCH DRIVEN LEDs for Compact Plants with High THC/CBD Outputs UV-A Enriched Spectrum for Increased Cannabinoid Production GACP/GMP Facility Suitable Since 2009 we have been committed to creating the best LED grow lights on the market so as to enable growers to increase yields, quality and energy savings. With the largest patent portfolio in the cannabis lighting industry, we are the pioneers of the high quality horticultural LED solutions. 31% 16% 28% more more total more compact plants cannabinoid flowers yield ...than with HPS. 7% 6% 4% more more total more compact plants cannabinoid THC yield ...than with competitor’s LEDs.
    [Show full text]
  • Cannabis Legal Regulatory Update January
    Allen & Overy | Cannabis Legal & Regulatory Update View this email in your browser Cannabis Legal & Regulatory Update January ­ March 2019 PDF version The A&O view In the last couple of months, the WHO Expert Committee on Drug Dependence (ECDD)’s recommendations on rescheduling cannabis and its derivatives in the international drug conventions have filled the cannabis industry with hope. Removing cannabis from the strictest Schedule IV (also including heroin and cocaine) is a logical – and overdue – step given the well­established medical use of the plant. However, in particular a vote in favour of removing cannabis “extracts and tinctures” from Schedule I (as recommended by the ECDD) may open up new possibilities for the CBD industry, which often faces legal hurdles on this basis given that CBD is not a scheduled substance in itself. We may soon expect approval of the first EU­wide approved cannabis­based medicine (Epidyolex®), and the European Parliament Resolution on the use of cannabis for medical purposes, which clearly recognises its medical use and specifically calls on the EU Commission and Member States for more research and innovation in this respect, will likely make us see more of these in the future. Many EU member states and other countries have recently authorised medical cannabis (e.g. UK) or are in the process of doing so (e.g. France), in order to provide access to patients but simultaneously being aware of the extra source of state income such authorisation represents. These positive recent developments in the medical sphere could nevertheless reinforce the idea of only two categories of cannabis – licit medical use vs.
    [Show full text]
  • Friday, September 12
    conference 2017 IACM 9th Conference on Cannabinoids in Medicine 29-30 September 2017 Cologne, Germany PROGRAM AND ABSTRACTS Place Maritim Hotel Heumarkt 20 50667 Cologne Germany Registration Fee The registration fee is 350 Euros. Students pay a reduced fee of 150 Euros. The registration fees include daily rates (lunch for all days, coffee during the breaks) and an evening dinner on Saturday. Organizer International Association for Cannabinoid Medicines (IACM) Am Mildenweg 6 59602 Rüthen Germany Phone: +49-2952-9708571 E-mail: [email protected] Internet: http://www.cannabis-med.org SCIENTIFIC AND ORGANIZING COMMITTEE Donald Abrams Ethan Russo Franjo Grotenhermen Kirsten Mueller-Vahl Mark Ware Roger Pertwee www.cannabinoidconference2017.org 2 Sponsors We gratefully acknowledge sponsoring by: Platin Sponors Gold Sponsors 3 Sliver Sponsors Bronze Sponsors 4 GENERAL INFORMATION Simultaneous translation There will be simultaneous translation from english into german. Badges Please wear your badge at all times during the conference. You will also need to wear it for the evening dinner. Dinner of IACM partner organizations and ambassadors On Friday we will have a dinner with the IACM partner organizations and ambassadors. Conference Dinner On Saturday evening we will have our gala dinner at the conference place. IACM Awards During the conference dinner the IACM will honour six people for their major contributions to cannabinoid research and/or to the re-introduction of cannabis into modern medicine with the IACM Award. IACM General Meeting The IACM will hold its general meeting on Saturday afternoon. Poster Sessions There will be two poster sessions at the conference: Session 1: Friday 13:00 – 15:00 during and after the lunch break.
    [Show full text]
  • Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark
    Research JAMA Psychiatry | Original Investigation Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark Carsten Hjorthøj, PhD; Christine Merrild Posselt, MSc; Merete Nordentoft, DrMedSc Editorial IMPORTANCE Cannabis use and potency of cannabis have increased during the past 2 Multimedia decades. If the association between cannabis use and schizophrenia is causal, this should be reflected in an increase in the proportion of cases of schizophrenia being attributable to Supplemental content cannabis, the population-attributable risk fraction (PARF). OBJECTIVE To determine whether the PARF for cannabis use disorder in schizophrenia has increased over time. DESIGN, SETTING, AND PARTICIPANTS This nationwide, register-based historical prospective cohort study included all people in Denmark born before December 31, 2000, who were alive and 16 years or older at some point from January 1, 1972, to December 31, 2016. Data analysis was performed from August 2020 to April 2021. EXPOSURE Diagnosis of cannabis use disorder. MAIN OUTCOMES AND MEASURES Diagnosis of schizophrenia, with estimated PARF of cannabis use disorder in schizophrenia from 1972 to 2016. RESULTS A total of 7 186 834 individuals were included in the analysis, including 3 595 910 women (50.0%) and 3 590 924 men (50.0%). The adjusted hazard ratio for schizophrenia Author Affiliations: Copenhagen fluctuated at approximately 4 (with 95% CIs ranging from approximately 3 to 6) throughout Research Center for Mental Health–
    [Show full text]
  • A Report O Drug Mark a Report on Global Illicit Drug Markets 1998-2007
    Full Report Full EUROPEAN COMMISSION EUROPEAN COMMISSION A ReportA Reporton Global on IllicitGlobal Illicit DrugA Report on Global Illicit Drug1998-2007 Markets MarketsDrug Markets 1998-2007 1998-2007 Full ReportFull Report Numéro de catalogue ISBN-13 Numéro de catalogue ISBN-13 NE-80-09-576-EN-C 978-92-79-119N45-E-80-03 9-576-EN-C 978-92-79-11945-3 A Report on Global Illicit Drugs Markets 1998-2007 Full Report Editors: Peter Reuter (RAND) and Franz Trautmann (Trimbos Institute) http://ec.europa.eu www.trimbos.nl www.rand.org/randeurope This study has been produced by the Trimbos Institute and RAND with the financial support of the Commission of the European Communities (contract JLS/2007/C4/005). The study does not necessarily reflect the opinions and views of the European Commission, nor is it bound by its conclusions. More information on the European Union and drug policy can be found on the following website: http://ec.europa.eu/justice_home/fsj/drugs/fsj_drugs_intro_en.htm Cataloguing data can be found at the end of this publication. ISBN-13: 978-92-79-11945-3 © European Communities, 2009 Acknowledgements - A Report on Global Illicit Drugs Markets 1998-2007 Acknowledgements The authors would like to thank all people who contributed to this study. We owe a large debt to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in Lisbon for the relevant input and support we received on many issues. The EMCDDA proved to be a particularly valuable source of information and expertise for our purposes. We want to express special thanks to Paul Griffiths, Brendan Hughes, Rosemary de Sousa and Frank Zobel who provided high quality information, data and advice throughout the project, as well as to their colleagues who contributed to specific sections in this report.
    [Show full text]